LINC01166: A Potential Drug Target and Biomarker (G101927590)

Target Name: LINC01166

NCBI ID: G101927590

LINC01166

Other Name(s): Long intergenic non-protein coding RNA 1166, transcript variant 1 | long intergenic non-protein coding RNA 1166

LINC01166: A Potential Drug Target and Biomarker

LINC01166 is a long intergenic non-protein coding RNA (lncRNA) with a transcript variant number of 1. It is a non-coding RNA molecule that has been identified in various organisms, including humans. LINC01166 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Recent studies have suggested that LINC01166 may be a potential drug target and biomarker. In this article, we will explore the potential mechanisms by which LINC01166 can be targeted as a drug and its potential as a biomarker for various diseases.

Mechanisms of LINC01166 as a Drug Target

LINC01166 has been shown to interact with various protein molecules, including the protein tyrosine kinase (PTK) signaling pathway. This interaction suggests that LINC01166 may be a drug target that can be inhibited or modulated to treat various diseases.

One of the potential targets of LINC01166 is the PTK signaling pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival. LINC01166 has been shown to regulate the activity of the PTK protein, which is involved in the treatment of various cancers, including breast, lung, and ovarian cancers.

Additionally, LINC01166 has also been shown to interact with the protein FAK, which is involved in cell adhesion and migration. This interaction suggests that LINC01166 may also be a drug target that can be used to treat diseases that are characterized by the disruption of cell adhesion and migration, such as cancer.

Mechanisms of LINC01166 as a Biomarker

LINC01166 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. This suggests that it may be a biomarker for various diseases.

One of the potential applications of LINC01166 as a biomarker is its potential to be used as a diagnostic biomarker for cancer. LINC01166 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancers. This suggests that LINC01166 could be used as a diagnostic biomarker for these cancers.

Another potential application of LINC01166 as a biomarker is its potential to be used as a therapeutic target for various diseases. As a drug target, LINC01166 may be used to treat diseases that are characterized by the disruption of cell adhesion and migration, such as cancer. Additionally, LINC01166 may also be used to treat other diseases that are characterized by the misregulation of cellular processes, such as neurodegenerative diseases.

Conclusion

In conclusion, LINC01166 is a long intergenic non-protein coding RNA that has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. Its potential as a drug target and biomarker make it an attractive target for further research. Further studies are needed to fully understand the mechanisms of LINC01166 and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1166

The "LINC01166 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01166 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets